Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERKLIN 2
2018-004788-30Phase 2Terminated
- Sponsor
- 4SC AG
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Domatinostat and avelumab in Merkel cell carcinoma (MCC), sponsored by 4SC AG. Primary endpoint: Objective Response Rate. Started Sep 2019; status: terminated.
02
Drugs
Domatinostatavelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2018-004788-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004788-30.